Securities code: 002940 securities abbreviation: Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) Announcement No.: 2022-015 Zhejiang Anglikang Pharmaceutical Co.Ltd(002940)
2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special note: the financial data of 2021 contained in this announcement is only preliminary accounting data, which has been audited by the company’s internal audit department and has not been audited by an accounting firm. It may be different from the final data disclosed in the annual report. Investors are reminded to pay attention to investment risks.
1、 Main financial data and indicators in 2021
Unit: Yuan
Increase and decrease of the project in the same period of last year in the reporting period
Total operating revenue 1421164958.53 1289647101.26 10.20%
Operating profit 159266938.93 211681010.13 – 24.76%
Total profit 157560198.33 210745333.17 – 25.24%
105101982.08 163719116.52 – 35.80% net profit attributable to shareholders of listed companies
After deducting non recurring profits and losses
98798866.33 134000807.56 – 26.27% net profit attributable to shareholders of listed companies
Basic earnings per share (yuan) 1.10 1.81 – 39.23%
Weighted average return on net assets 8.03%, 16.11% – 8.08%
Increase and decrease at the end of the reporting period
Total assets 1999679207.89 1940754044.72 3.04%
1324110874.84 1318879304.06 0.40% owner’s equity attributable to shareholders of listed companies
Share capital 95946819.00 95946819.00 0.00%
13.80 13.75 0.36% net assets per share attributable to shareholders of listed companies (yuan)
Note: the above data are filled in with the data of the company’s consolidated statements.
2、 Description of operating performance and financial status
1. During the reporting period, the company achieved a total operating income of 142.116 million yuan, a year-on-year increase of 10.20%; The net profit attributable to the shareholders of the listed company was 105.012 million yuan, a year-on-year decrease of 35.80%. The main reasons for the decline in performance during the reporting period are: ① the government subsidies received decreased compared with the same period of last year; ② The increase in losses of associated enterprises and the recognition of investment losses in the merger of Fujian Haixi United Pharmaceutical Co., Ltd. resulted in a decrease in investment income over the same period of last year; ③ R & D expenses increased over the same period last year.
2. As of December 31, 2021, the total assets of the company were 1999679200 yuan, an increase of 3.04% over the beginning of the period; The owner’s equity attributable to the shareholders of the listed company was 1324110900 yuan, an increase of 0.40% over the beginning of the period. 3、 Description of the difference from the previous performance forecast
Before the disclosure of this performance express, according to the relevant regulations of the exchange, the company did not make an expected disclosure of the operating performance in 2021.
4、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting and the person in charge of accounting organization;
2. The internal audit report signed by the head of the internal audit department.
Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) board of directors
February 26, 2022
